Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2017
Price :
$35
*
At a glance
- Drugs PRX 3140 (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors EPIX Pharmaceuticals
- 02 Oct 2017 According to a Ology Bioservices media release, Nanotherapeutics changed its name to Ology Bioservices.
- 17 Jan 2008 Amended results were reported in a EPIX Pharmaceuticals media release.
- 19 Dec 2007 Status changed from in progress to completed.